Video

Dr. Kunz on Sequencing Agents for Pancreatic NETs

Pamela L. Kunz, MD, assistant professor, Division of Oncology, Stanford University School of Medicine, discusses sequencing agents for the treatment of pancreatic NETs.

Pamela L. Kunz, MD, assistant professor, Division of Oncology, Stanford University School of Medicine, discusses sequencing agents for the treatment of pancreatic NETs.

The appropriate sequencing of agents in this area is an important unanswered question. Currently, there are no head-to-head trials looking at what agents should be given in the first line.

Today, academic and community oncologists must weigh patient characteristics (pace of disease growth, tumor bulk, grade, and patient preference) and drug characteristics (method of administration and side effects) to make their decision on a first line agent.

<<<

View more from NANETS

Related Videos
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss ongoing research in gastrointestinal cancers.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss research building upon approved combinations in unresectable hepatocellular carcinoma.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on trastuzumab deruxtecan–based regimens in advanced HER2-positive GI cancers.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on tremelimumab/durvalumab vs atezolizumab/bevacizumab in unresectable HCC.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on 5-year data for tremelimumab plus durvalumab in unresectable HCC.
Tanios Bekaii-Saab, MD, FACP
Michel Ducreux, MD, PhD, head, Gastrointestinal Oncology Unit, head, Gastrointestinal Oncology Tumor Board, Gustave Roussy; professor, oncology, Paris-Saclay University
Piotr Rutkowski, MD
Yelena Y. Janjigian, MD
Zhi Peng, MD